NOT FOR DISTRIBUTION
Header cover image

Market Cap

kr104.4m

Last Updated

2021/04/18 17:40 UTC

Data Sources

Company Financials

Executive Summary

Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Promore Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PROMO is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PROMO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.


Market Performance


7 Day Return

3.4%

PROMO

1.1%

SE Biotechs

2.1%

SE Market


1 Year Return

-39.8%

PROMO

14.7%

SE Biotechs

61.9%

SE Market

Return vs Industry: PROMO underperformed the Swedish Biotechs industry which returned 14.9% over the past year.

Return vs Market: PROMO underperformed the Swedish Market which returned 61.7% over the past year.


Shareholder returns

PROMOIndustryMarket
7 Day3.4%1.1%2.1%
30 Day-7.0%2.1%6.8%
90 Day-5.1%-2.7%16.9%
1 Year-39.8%-39.8%15.0%14.7%65.9%61.9%
3 Year-73.8%-77.4%20.3%17.9%74.3%55.7%
5 Yearn/a36.7%21.4%109.3%68.3%

Long-Term Price Volatility Vs. Market

How volatile is Promore Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Promore Pharma undervalued compared to its fair value and its price relative to the market?

4.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PROMO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PROMO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PROMO is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.

PE vs Market: PROMO is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PROMO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PROMO is good value based on its PB Ratio (4.6x) compared to the SE Biotechs industry average (5x).


Future Growth

How is Promore Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Promore Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Promore Pharma performed over the past 5 years?

-34.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PROMO is currently unprofitable.

Growing Profit Margin: PROMO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PROMO is unprofitable, and losses have increased over the past 5 years at a rate of 34.6% per year.

Accelerating Growth: Unable to compare PROMO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PROMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.9%).


Return on Equity

High ROE: PROMO has a negative Return on Equity (-129.03%), as it is currently unprofitable.


Financial Health

How is Promore Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: PROMO's short term assets (SEK25.2M) exceed its short term liabilities (SEK2.6M).

Long Term Liabilities: PROMO's short term assets (SEK25.2M) exceed its long term liabilities (SEK820.0K).


Debt to Equity History and Analysis

Debt Level: PROMO's debt to equity ratio (3.1%) is considered satisfactory.

Reducing Debt: PROMO's debt to equity ratio has reduced from 16.6% to 3.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PROMO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PROMO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.5% each year


Dividend

What is Promore Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PROMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PROMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PROMO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PROMO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PROMO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average board tenure


CEO

Jonas Ekblom (55 yo)

11.25yrs

Tenure

kr1,575,067

Compensation

Dr. Jonas Ekblom, Ph.D. has been Director at CombiGene AB (publ) since 2020. Dr. Ekblom has been the Chief Executive Officer of Pergamum AB since November 1, 2010 and serves as its President. Dr. Ekblom se...


Board Members

Experienced Board: PROMO's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Promore Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Promore Pharma AB (publ)
  • Ticker: PROMO
  • Exchange: OM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr104.367m
  • Shares outstanding: 36.43m
  • Website: https://www.promorepharma.com

Number of Employees


Location

  • Promore Pharma AB (publ)
  • Karolinska Institutet Science Park
  • Fogdevreten 2
  • Solna
  • Stockholm County
  • 171 65
  • Sweden

Listings


Biography

Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 for the prevent...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/18 17:40
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.